Findings

What do systematic reviews say?

71 questions · 72 findings · 26 reviews · Common Mental Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 33 · 45.8%GRADE not reported 2 · 2.8%Very low 20 · 27.8%Low 9 · 12.5%Moderate 6 · 8.3%High 2 · 2.8%

Antidepressants vs antidepressants

Quality of life · adults with psychotic depression

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antidepressant plus antipsychotic vs placebo plus antidepressant

Quality of life · adults with psychotic depression

The review found no eligible studies for this question.

2 findings from 1 review

Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antidepressants vs antipsychotics

Quality of life · adults with psychotic depression

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antidepressants vs placebo

Quality of life · adults with psychotic depression

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs placebo plus antidepressant

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs placebo plus antidepressant

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Augmentation of current antidepressant (various) with cariprazine (1 mg/d to 4.5 mg/d) vs augmentation of current antidepressant (various) with placebo

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with olanzapine (5 mg/d to 20 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with placebo

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

Quality of life (EQ‐5D‐5L) ‐ 12 weeks · treatment‐resistant depression in adults

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 447 participants
High

Antidepressant plus antipsychotic vs placebo

Quality of life · adults with psychotic depression

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antidepressant plus antipsychotic vs placebo/no adjunctive treatment + antipsychotics

Quality of life · adults with psychotic depression

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Discontinuation of long‐term antidepressant with minimal intervention vs usual care

Quality of life · participants with long‐term antidepressants for depressive or anxiety disorders

1 finding from 1 review

Approaches for discontinuation versus continuation of long‐term antidepressant use for depressive and anxiety… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 146 participants
Very low

Augmentation of current antidepressant (various) with quetiapine (150 mg/d to 300 mg/d) vs augmentation of current antidepressant (various) with placebo

Quality of life (% max score of Q‐LES‐Q‐SF) ‐ Any dose Scale from: 0 to 100 (better) · treatment‐resistant depression in adults

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 884 participants
Moderate

Antidepressants vs placebo

Quality of life score at 8 weeks · adults living with HIV and depression

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 87 participants
Very low

Tricylic antidepressant vs placebo

Change in quality of life · chronic obstructive pulmonary disease (COPD) with depression

1 finding from 1 review

Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low

Abrupt discontinuation vs continuation of long‐term antidepressants

Quality of life · participants with depressive or anxiety disorders

The review found no eligible studies for this question.

1 finding from 1 review

Approaches for discontinuation versus continuation of long‐term antidepressant use for depressive and anxiety… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Exercise therapy plus antidepressants vs antidepressants alone

QoL · men and women aged over 18 years with chronic fatigue syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Exercise therapy for chronic fatigue syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Switching to mianserin (60 mg/d) vs continuing on current antidepressant (fluoxetine 20 mg/d)

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antidepressants vs a combination of medications

Quality of life at post‐treatment Indexed by self‐report measures of quality of life or functional disability · somatoform disorders in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for somatoform disorders in adults 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found